On the other hand, Vorasidenib, an oral Isocitrate Dehydrogenase (IDH1/2) inhibitor, recently approved for IDH-mutant gliomas, significantly prolongs progression-free survival [164]. Here, IDH1 is linked to central nervous system cancer.